Last updated: February 26, 2026
What is the drug associated with NDC 73043-0014?
NDC 73043-0014 corresponds to Prolia (denosumab), a monoclonal antibody used primarily for osteoporosis treatment, bone metastases, and other related conditions. Prolia is marketed by Amgen Inc.
What is the current market landscape for Prolia?
Market Size and Sales Trends
- Global sales of Prolia reached approximately $2.9 billion in 2022.
- U.S. sales account for around 60-70% of global revenue.
- The drug's revenue has grown at an average annual rate of approximately 7% since 2018.
Key Competitors
- BTS (Bisphosphonates): Alendronate, risedronate, ibandronate
- Other biologics: Evenity (romosozumab), Forteo (teriparatide)
- Emerging treatments: Novel agents targeting different pathways for osteoporosis and bone metastases
Market Segments
- Osteoporosis in postmenopausal women
- Osteoporosis in men
- Bone metastases in cancer patients
- Multiple myeloma
Geographic Distribution
- U.S.: Largest market, with approximately 65% of sales
- Europe: Around 25%
- Rest of World: 10%
What are the key factors shaping future market performance?
Approvals and Line Extensions
- Pending or recent approvals in new indications (e.g., early osteoporosis in men)
- Development of biosimilars, which may impact pricing and market share
Patent Status and Biosimilar Entry
- Patent expiry anticipated around 2029
- Several biosimilar development programs underway, with expected market entry by 2030
Pricing Dynamics
- Average list price per dose in the U.S. is approximately $2,150
- Typical treatment course involves 6 doses per year
- Indirect pricing (negotiated discounts, rebates) reduces net prices by 20-30%
Reimbursement and Market Access
- U.S.: Reimbursed primarily through Medicare Part B and commercial insurers
- Price negotiations and formulary placements influence access and sales volumes
What are the projected price trends?
| Year |
Estimated Average Price per Dose |
Notes |
| 2023 |
$2,150 |
Current list price |
| 2025 |
$2,100 - $2,200 |
Slight decline due to biosimilar competition |
| 2030 |
$1,800 - $2,000 (biosimilar impact) |
Industry estimates anticipate biosimilar price erosion |
Price Drivers
- Biosimilar introductions are expected to drive prices downward by 10-20% within 3-5 years post-entry.
- Payer negotiation strategies may further influence net prices.
- Emerging indications and expanded labelings could support sustained pricing if payers recognize therapeutic value.
What are the financial implications?
- Revenue projections suggest moderate growth through 2025, with potential stagnation or decline approaching biosimilar market entry.
- If biosimilar prices settle around $1,200 - $1,500 per dose, market share shifts could reduce overall revenue.
Summary of key insights
- The current market for Prolia is approximately $2.9 billion annually.
- U.S. sales dominate, with growth driven by expanded indications.
- Biosimilar competition is expected to emerge around 2029-2030, likely reducing prices by up to 20-25%.
- The average price per dose is trending downward, from around $2,150 in 2023 to approximately $1,800-$2,000 by 2030.
Key Takeaways
- Prolia holds a substantial market share within osteoporosis and bone metastasis treatments.
- Patent expiration and biosimilar entry are primary factors influencing future pricing and sales.
- Price decline estimates posit a decrease of 10-20% over the next five years, accelerated by biosimilar market entry.
- U.S. market dominance remains, but global growth will depend on reimbursement policies and access.
- The overall revenue outlook remains stable through 2025, with potential contraction thereafter.
FAQs
Q1: When is the patent for Prolia expected to expire?
Patent protection is anticipated to expire around 2029, enabling biosimilar development.
Q2: How are biosimilar prices expected to compare to Prolia?
Biosimilars are projected to enter at 10-20% lower than originator prices, around $1,200 - $1,500 per dose.
Q3: What factors could accelerate price declines?
Early biosimilar approval, payer negotiations, and broader adoption of generics/biosimilars.
Q4: How does Reimbursement in the U.S. affect pricing?
Reimbursement largely through Medicare Part B and private insurers influences net pricing; negotiations often result in discounts.
Q5: Are there new indications for Prolia that could affect market size?
Yes, ongoing trials in early osteoporosis and other bone-related conditions could support additional sales.
References
- Amgen Inc. (2022). Prolia (denosumab) prescribing information.
- IQVIA. (2023). Global Bone Health Therapeutics Market Report.
- US Food and Drug Administration. (2023). Biosimilar Approval Track Record.
- EvaluatePharma. (2023). World Preview 2023, Outlook to 2028.
- Pharma Intelligence. (2023). Biosimilars Pricing and Market Impact.
